Reliance Global Group Expands Into Radiopharmaceuticals with Investment

Reliance Global Group ( (EZRA) ) has issued an update.

Reliance Global Group has formed LifeSci Global Group LLC as a majority-owned vehicle to invest in healthcare and early-stage life sciences companies, funding its deals via loans from the company and its subsidiary EIG. The move extends Reliance’s reach beyond InsurTech into high-growth medical technologies, aligning with a broader strategy to build exposure to innovation-driven platforms.

On April 30, 2026, LifeSci Global completed an initial investment of about $2 million in Innervate Radiopharmaceuticals, a late-stage developer of PET imaging and therapeutic radiopharmaceuticals initially targeting neuroblastoma, funded in part through a $2 million promissory note bearing 7% interest. The deal, reviewed and approved solely by independent directors due to related-party interests, gives Reliance a stake in a radiopharmaceutical platform with an estimated $250 million neuroblastoma opportunity and potential billion-dollar cardiovascular and neurodegenerative markets.

To address conflicts tied to director Scott Korman’s leadership role at Innervate and equity interests in LifeSci Global, the board reconstituted its audit, compensation and nominating committees on April 28, 2026, removing Korman and appointing independent directors as members and chairs. These changes left all three committees composed entirely of independent directors under Nasdaq and SEC rules, while Korman remained on the board, signaling a focus on governance as Reliance broadens into healthcare investment.

Spark’s Take on EZRA Stock

According to Spark, TipRanks’ AI Analyst, EZRA is a Neutral.

The score is held down primarily by weak financial performance—persistent net losses and consistent negative operating/free cash flow—despite 2025 balance-sheet de-risking. Technicals remain bearish on longer timeframes (below key moving averages, negative MACD). Offsetting factors include high headline dividend yield and a more constructive narrative from the earnings call and recent events around strategic realignment, liquidity actions, and platform/technology initiatives, though these remain execution- and milestone-dependent.

To see Spark’s full report on EZRA stock, click here.

More about Reliance Global Group

Reliance Global Group, Inc., listed on Nasdaq as EZRA, is an InsurTech company that applies artificial intelligence and cloud-based technologies to streamline the insurance agency and brokerage sector. Its RELI Exchange platform serves business-to-business clients, while its 5minuteinsure.com site targets consumers seeking rapid auto, home and life insurance quotes, alongside a portfolio of U.S. retail agencies.

Beyond its core insurance and InsurTech activities, Reliance operates EZRA International Group as a strategic growth platform focused on high-growth technology and life sciences assets. Through this arm, the company seeks minority and control stakes in innovative businesses where it can use disciplined capital allocation and active strategic involvement to enhance long-term shareholder value.

Average Trading Volume: 16,547,727

Technical Sentiment Signal: Sell

Current Market Cap: $3.61M

For an in-depth examination of EZRA stock, go to TipRanks’ Overview page.